and anti-RNA polymerase antibody. The purpose of this study was to investigate tumor necrosis factor (TNF) polymorphisms in scleroderma, with the specific aim of determining whether TNF ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Avonex is an injectable solution prescribed for relapsing forms of multiple sclerosis (MS ... to avoid prescribing Avonex with a monoclonal antibody. However, the interaction is stronger with ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

A specific autoantibody signature was seen in a subset of people with multiple sclerosis (MS ... "We know B cells -- the cells that make antibodies -- are crucial for MS disease progression ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Long-term safety data in MS patients for the highly specific ... IgG4κ antibody raised against α4-integrin (CD49d) was approved for the treatment of relapsing-remitting multiple sclerosis ...

PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s ...

This study aimed to employ a global antibody profiling strategy ... in the development of systemic sclerosis (SSc), particularly those not linked to well-defined autoantigens, remains largely unknown.

Multiple sclerosis (MS) is a chronic disease of the ... count), vasculitis (high white blood cell count), and infection (a specific pattern of high white blood cells). This would be the first ...

If you've been diagnosed with multiple sclerosis (MS), it's time to start exploring treatment ... but that usually stops happening as treatment continues. Depending on the specific interferon you are ...

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.